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In recent years, peroxisome proliferator-activated receptors (PPARs) have received growing interest due to the broad spectrum
of their biological activities. PPARα, an isoform of PPAR, plays an important role in lipid homeostasis and inﬂammation, which
makes it a potential target for the treatment of chronic inﬂammatory disorders, including RA. This paper reviews studies on the
properties of PPARαagonistswhich maybe pertinent to the treatment ofRA. These properties include eﬀects onlipidmetabolism,
inﬂammation, and angiogenesis, as well as interference with glucocorticoid eﬀects, and a potential role in gender dimorphism of
autoimmune disorders. However, current clinical experience with this class of drugs in RA is limited. New studies are needed to
elucidate whether PPARα agonism may be an eﬀective treatment strategy for RA patients.
1.Introduction
The nuclear hormone receptor superfamily is a large group
of related receptors which are able to bind a broad-
ranging array of ligands. The peculiarity of nuclear receptors
is that upon activation, they act as transcription factors
binding to a speciﬁc DNA sequence resulting in changes
in gene expression. The nuclear receptor superfamily is
divided into six subfamilies and 26 groups of receptors.
Subfamily 1 is represented by peroxisome proliferator-
activated receptors (PPARs) (Nuclear Receptors Nomencla-
ture Committee, 1999) [1], which play a major role in
lipid metabolism, glucose homeostasis, and inﬂammatory
processes. Three isotypes of PPAR have been described:
(1) PPARα, also known as nuclear receptor subfamily 1,
group C, member 1 (NR1C1), (2) PPARβ/δ (NR1C2), and
(3) PPARγ (NR1C3). These isotypes have diﬀerent tissue
distribution, functions, and ligand speciﬁcity. In particular,
PPARα is highly expressed in the liver, heart, brown adipose
tissue, skeletal muscle, and kidney. Its expression has also
been proven on dendritic cells, macrophages, and B and
T cells [2]. There are both natural and synthetic ligands
of PPARα. Endogenous ligands are mainly unsaturated
or polyunsaturated fatty acids and eicosanoids and need
to be at micromolar concentrations to achieve PPAR
activation [3], except 1-palmitoyl-2-oleoyl-sn-glycerol-3-
phosphocholine (16:0/18:1 GPC) which has nanomolar
aﬃnity [4]. Synthetic agonists of PPARα are hypolipidemic
drugs (fenoﬁbrate,gemﬁbrozil,cloﬁbrate,nafenopin, methyl
clofenapate, tibric acid, and Wy-14,643) which act at the
nanomolar range. PPARα has been proposed as a key lipid
metabolism modulator and regulator of inﬂammation [2].
Therefore, these properties of PPARα make it a possible
target for therapy in rheumatoid arthritis (RA), which is
characterized by accelerated atherosclerosis and impaired
lipid proﬁle [5]. This paper will summarize the data on
PPARα biological functions with implications to the treat-
m e n to fa u t o i m m u n ed i s o r d e r sa sw e l la st h ec u r r e n tc l i n i c a l
experience with PPARα agonists in RA.
2.PPARαand LipidMetabolism
PPARα induces gene transcription after forming het-
erodimers with the 9-cis retinoic X receptor (RXR). Then
these heterodimers bind to speciﬁc DNA sequences called2 International Journal of Rheumatology
Peroxisome Proliferator Response Elements (PPREs) in the
promoter regions of multiple target genes forming the so-
called PPARα transcriptome (Figure 1)[ 6].
In the liver, activation of PPARα promotes fatty acid
oxidation, ketone bodies synthesis, and glucose sparing via
the induction of various protein synthesis such as fatty acid
transport proteins and acyl-CoA oxidase [2].
In terms of lipoprotein metabolism, PPARα activation
results in changes in transcription of multiple genes includ-
ing LPL, APOC3, PCKK9, ANGPTL3, APOA1, APOA2, and
APOA5 [7]. A well-known eﬀect of ﬁbrates is a reduction
in plasma triglyceride levels. This is thought to be a
result of enhanced lypolysis of very low density lipoprotein
(VLDL) triglyceride induced by changes in LPL, APOC3,
and APOA5 transcription. APOA1, APOA2 transcription
changes result in enhanced apoA-I and apoA-II production
leading to increased high density lipoprotein cholesterol
(HDL-c) concentrations [7].
The lipid-modulating properties of ﬁbrates suggest that
they may improve impaired lipid proﬁle observed in RA
patients (Table 1). Thus, although triglycerides are less
strongly associated with cardiovascular risk in RA patients
than in people without RA [8], their reduction induced
by ﬁbrate treatment may be of beneﬁt. Moreover, in one
study it has been shown that, under ﬁbrate treatment,
only triglycerides were independent predictors of CHD
[9].
Another important lipid target of ﬁbrates is HDL-
c whose concentrations are decreased in RA and have
been linked to excess cardiovascular events in some studies
[10].
Apart from their beneﬁcial action, ﬁbrates may have
some undesirable metabolic eﬀects, particularly increased
homocysteine levels [11]. Homocysteine reduces apoA-I
synthesis in the liver leading to decreased plasma apoA-I
levels[12].Ithasbeenshown thathigherhomocysteinelevels
correlate with smaller increases in HDL and apoA-I after
fenoﬁbrate treatment [13]. Fenoﬁbrate eﬀects on oxidized
lowdensitylipoprotein(oxLDL),which iselevatedinRAand
probably linked with cardiovascular morbidity [14], are also
diminished by high levels of homocysteine [15]. It should
be noted that homocysteine itself is an independent risk
factor of cardiovascular disease in RA [16] ,a l t h o u g h ,t od a t e
homocysteine-lowering treatment has not been proven to
be eﬀective in reducing cardiovascular outcomes, possibly
due to not taking into account baseline homocysteine
concentrations [17]. As the majority of patients with RA
are now taking folate as supplementation to methotrexate
treatment, it may lead to serum homocysteine reduction
and thus improve lipid-modulating eﬀects of fenoﬁbrate,
enhancing its action on HDL, apoA-I, and oxLDL.
3.Anti-InﬂammatoryActionofPPARα
A number of in-vitro studies exploiting diﬀerent experi-
mental models have investigated eﬀects of PPARα agonists
on inﬂammation markers. It has been found that PPARα
agonists inhibited inducible nitric-oxide synthase activity
in murine macrophages [21], and VCAM-1 expression in
endothelial cells [22]. In human aortic smooth muscle cells
(SMC), PPARα agonists reduced IL-1 induced production
of IL-6, prostaglandin, and expression of COX-2 [23, 24].
In addition, PPARα ligands induced apoptosis of human
monocyte-derived macrophages activated by TNF-α or IFN-
γ [25].
The ﬁrst evidence of the in-vivo anti-inﬂammatory
action of PPARα agonists in humans came from the
studies performed on patients with hyperlipidemia and
metabolic syndrome. Thus, fenoﬁbrate treatment decreased
plasma concentrations of IL-6, ﬁbrinogen, and C-reactive
protein [24] in hyperlipidemic patients. In another study
performed on hyperlipoproteinemia IIb and atherosclero-
sis patients, micronized fenoﬁbrate reduced serum TNF-
α and IFN-γ concentrations [26]. These results have been
conﬁrmed by a small randomized placebo-controlled study
in patients with metabolic syndrome, showing decreases
in high-sensitivity C-reactive protein and IL-6 levels fol-
lowing fenoﬁbrate therapy. These fenoﬁbrate eﬀects were
independent of its eﬀects on lipid and glucose metabolism
[27].
Several studies have sought to characterize the molec-
ular mechanisms implicated in the downmodulation of
inﬂammatory mediators by PPARα activation. As a result,
it has been demonstrated that PPARα exerts its eﬀects on
proinﬂammatory cytokine gene expression by antagonizing
the AP-1 and nuclear factor κB( N F - κB) transcriptional
activities in human aortic SMC [24, 28]. An additional
molecularmechanismofPPARαagonists’anti-inﬂammatory
action is induction of the expression of the NF-κB inhibitory
protein IκBα found in SMC as well as in primary human
hepatocytes (Figure 2)[ 29].
ThebiologicalroleofPPARα-inducedanti-inﬂammatory
eﬀects seems to be the control of inﬂammatory response
duration. This control is probably mediated by endogenous
PPARα ligand leukotriene B4 (LTB4), which is a power-
ful chemotactic inﬂammatory eicosanoid. PPARα activa-
tion leads to transcription of genes of the β-a n dω-
oxidation pathways that neutralize and degrade LTB4 itself,
thus regulating inﬂammation by a negative feedback loop
[30].
The experimental and clinical studies relevant to
atherosclerosis and dyslipidemia were followed by the work
of Okamoto et al. [31] who assessed the anti-inﬂammatory
eﬀects of PPARα activation in rheumatoid synovial ﬁbrob-
lasts (RSF) cultures and in a rodent model of inﬂammatory
arthritis. Fenoﬁbrate reduced IL-1β-stimulated production
of IL-6, IL-8, and GM-CSF as well as nuclear translocation
of NF-kB in RSF. The therapeutic use of fenoﬁbrate leads to
clinical improvement and inhibited mononuclear cell inﬁl-
tration and reduced pannus formation in the synovial tissue
of rats with adjuvant-induced arthritis. Moreover, fenoﬁ-
brate inhibited osteoclast formation from human peripheral
blood mononuclear cells in-vitro.
Several other studies evaluated the eﬀects of PPARα
agonists on cytokine production in diﬀerent experimental
settings. Thus, fenoﬁbrate repressed interleukin-17 andInternational Journal of Rheumatology 3
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Figure 1: PPARα and lipid metabolism. PPARα forms heterodimers with RXR. The heterodimers bind to PPREs which leads to enhanced
expression of many genes involved in lipid metabolism.The main resulting changes are increased fatty acid oxidation, decreased triglyceride
concentration, and increased levels of HDL. RXR: retinoid X receptor, PPRE: peroxisome proliferator response elements, and HDL: high
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Figure 2: A hypothetical model for PPARα-induced anti-inﬂammatory eﬀects in rheumatoid arthritis. PPARα might suppress
transcriptional activity of NFκB by several mechanisms: directly, by inducing IκB transcription or by inhibition of NFκB migration into
nucleus. Another transcription factor AP-1 is also suppressed by PPARα.D o w nr e g u l a t i o no fN F κB and AP-1 results in reduced synthesis of
various mediators involved in joint inﬂammation and damage as well as in atherosclerotic plaque formation. NFκB: nuclear factor κB, IκB:
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Table 1: Some metabolic eﬀects of PPARα agonists with their relevance to RA.
Parameter Eﬀect of PPARα agonists Relevant changes in RA
TG ↓ [18] TG levels are weakly related to ischaemic stroke [8]
HDL
↑ [19], higher eﬀect correlates with lower serum
homocysteine concentrations [13] HDL-c levels are decreased [10]
Total cholesterol ↓ [18] No changes in total cholesterol revealed in a recent
meta-analysis [10]
oxLDL
No eﬀect due to increase in homocysteine, folic acid
coadministration may potentiate fenoﬁbrate
antioxidative capacity directed on oxLDL [15]
Increase of oxLDL concentrations [14]
Homocysteine ↑ [20] Homocysteine concentrations are increased; however,
this may be corrected by folic acid intake [16]
TG: triglyceride,HDL: high density lipoprotein, oxLDL: oxidized low density lipoprotein, ↑:i n c r e a s e ,↓: decrease.
interferon-gamma expression and decreased colonic lym-
phocyte inﬁltration in a colitis model in interleukin-10-
deﬁcient mice [32]. Fenoﬁbrate treatment also resulted in
clinical improvement and enhanced cardiac expression of
IL-10 mRNA in a rat model of experimental autoimmune
myocarditis [33].
T a k e nt o g e t h e r ,t h e s ed a t ag i v ear a t i o n a l ef o rP P A R α
agonists to be evaluated both as modulators of the inﬂam-
matory response and as a disease-modifying class of drug in
RA.
4.PPARαInterferencewith
GlucocorticoidEffects
It is known that PPARα is activated by glucocorticoids (GC)
duringfastingorstress [34].Recently,ithasbecomeapparent
that PPARα may itself modulate multiple biologicaleﬀectsof
GC.
Genomic mechanisms of GC action are mediated by
binding of GC to cytosolic GC receptors (cGCR). Then
GC/cGCR complex is translocated into the nucleus to
consensus palindromic DNA sites, which are called GC
responsive elements (GRE) [35]. Genes regulated by GRE
encode proteins involved in glucose, fat, and protein
metabolism. Alternatively, activated cGCR monomers can
also inﬂuencegene expression by interfering with the activity
of transcription factors NF-κBa n dA P - 1 ,w h i c hp l a yak e y
role in inﬂammatory mediator synthesis. There is a broad
consensus that GCs exert their anti-inﬂammatory eﬀects via
transrepression of NF-κB and AP-1 whereas detrimental side
eﬀects originate from the transactivation capacities of GR
mediated by GRE binding [35].
There have been several studies evaluating interactions
between the eﬀects of GC and PPARα activation. Riccardi et
al. studied anti-inﬂammatory eﬀects of dexamethasone on
experimental inﬂammatory bowel disease in PPARα knock-
out mice in comparison with wild type mice. The authors
found that dexamethasone was less eﬀective in PPARα null
mice as evaluatedby inhibition of proinﬂammatory cytokine
production, cell migration, oxidative stress, apoptosis, and
colon injury. These ﬁndings indicate that PPARα agonism
may contribute to the anti-inﬂammatory action of GC [36].
To elucidate molecular mechanisms of PPARα and GC
synergism, Bougarne et al performed a study evaluating a
functional cross-talk between PPARα-a n dG C R - m e d i a t e d
signalingpathways.Aswasexpected,simultaneousactivation
of PPARα and GCR enhanced transrepression of NF-κB-
driven genes and additively decreased proinﬂammatory
cytokine production. On the other hand, PPARα activation
inhibited the expression of classical GRE-driven genes, thus
acting as a potential antagonist to GC with respect to their
eﬀects on glucose, fat, and protein metabolism [37]. So it
can be hypothesized that PPARα agonists attenuate GC side
eﬀects while enhancing their anti-inﬂammatory activity via
transrepression of NF-κB( Figure 3).
5.PPARαand Angiogenesis
Angiogenesis, or formation of new capillaries from preexist-
ing vessels, is a characteristic feature of inﬂamed synovium
in RA and develops at the earliest stage of the disease
process. Angiogenesis is essential for the formation of the
inﬂammatory pannus, and without angiogenesis, leukocyte
migration could not occur [38].
The role of PPARα in angiogenesis is controversial. In
one study, fenoﬁbrate was shown to inhibit endothelial
cell proliferation induced by angiogenic factors, endothelial
cell migration in a healing wound model, capillary tube
formation in-vitro, and angiogenesis in-vivo [39]. Other
research has demonstrated antiangiogenic eﬀects of ﬁbrates
leading to suppressed tumor growth [40]. In contrast,
fenoﬁbrate enhanced neovascularization in a murine hind-
limb ischemia model [41] and in a murine corneal model of
angiogenesis [42].
Modulatory eﬀects of PPARα on angiogenesis seem to
be mediated by changes in the expression of diﬀerent pro-
angiogenic modulators, such as VEGF, ﬁbroblast growth
factors (FGF), thrombospondin, and endostatin [43].
In contrast with angiogenesis, vasculogenesis, which is
de novo capillary formation from endothelial precursor cells
(EPCs), is impaired in RA. Deteriorated function of EPC
mayleadtochangesinvasculogenesisresultinginaccelerated
atherosclerosis and vascular disease [44].International Journal of Rheumatology 5
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Figure 3: (a) a hypothetical mechanisms of PPARα interference with glucocorticoid eﬀects. GC/GCR complex binds to speciﬁc DNA sites
called GRE which results in increased expression of many genes encoding proteins involved in fat, glucose, and protein metabolism.Adverse
eﬀects of GC are thought to stem from GRE binding. GC/GCR also down regulates transcription factors NFκB and AP-1 thus suppressing
synthesis of inﬂammatory mediators. (b) PPARα further inhibits NFκB and AP-1 thus enhancing GC anti-inﬂammatory action. PPARα
inhibitionofGC/GCR-mediated GREactivationleadstoattenuationofGC-induced adverseevents.GC:glucocorticoid,GCR:glucocorticoid
receptor, GRE: glucocorticoid response element, NFκB: nuclear factor κB, IκB: inhibitor of κB, and AP-1: activator protein 1.
Using a PPARα−/− mouse model, Benameur et al. have
demonstrated thatEPC diﬀerentiationinducedby micropar-
ticles (small vesicles released from the plasma membrane of
stimulated or apoptotic cells) is dependent on PPARα and
mediated by the NF-κBp a t h w a y[ 45]. On the basis of this
study, it may be speculated that PPARα agonists improve
vasculogenesis via stimulation of EPC.
Thus, the eﬀects of PPARα on angiogenesis and vasculo-
genesis seem to be multidirectional and probably depend on
the local cytokine and growth factor balance as well as the
disease model studied.
6.PPARα,SexualDimorphism, and
Autoimmune Diseases
Apart from its importance in energy metabolism and
inﬂammation, PPARαhasbeenshown toplaya roleinsexual6 International Journal of Rheumatology
Table 2: Future research agenda.
(1) Anti-inﬂammatory, disease-modifying, and antiatherogenic
properties of PPARα agonists in RA patients have to be tested in a
randomized, placebo-controlled fashion.
(2) PPARα agonists’ability to enhance the anti-inﬂammatory
action of glucocorticoids and reduce their side eﬀects in
inﬂammatory rheumatic disorders should be assessed.
(3) The hypolipidemic and antiatherogenic eﬀects of PPARα
agonists need to be compared between subgroups of RA patients
taking or not taking supplemental folic acid.
dimorphism partly due to an ability to regulate female-
speciﬁc gene expression in the liver [46]. Dunn et al. have
further demonstrated that this aspect of PPARα biology
might be relevant in the context of autoimmune disease
pathogenesis. In their study, they found that PPARα was
more abundant in male as compared with female CD4 (+)
cells and its expression was sensitive to androgen levels.
Genetic ablation of PPARα resulted in higher production of
IFN-γ and TNF-α, and lower production of T helper (Th)2
cytokines due to upregulation of NF-κB and c-jun activity
in male T lymphocytes. Moreover, male, but not female,
PPARα (−/−) mice developed more severe experimental
autoimmune encephalomyelitis. The authors’ conclusion
is that males are less prone to develop Th1-mediated
autoimmunity because they have higher T-cell expression of
PPARα [47]. These ﬁndings allow one to hypothesize that
PPARα may be important in gender dimorphism in human
autoimmune disorders including RA.
7.ClinicalUse of PPARαAgonistsinRA
To date, the clinical experience with PPARα agonists in
RA is limited. First, a case report on a female patient
with refractory RA taking fenoﬁbrate showed long-lasting
improvement of her symptoms [48]. Goto reported a ran-
domized study of 44 RA patients comparing fenoﬁbrate and
statins. Fenoﬁbrate, but not statins, signiﬁcantly decreased
serum levels of total cholesterol, low density lipoprotein
cholesterol (LDL-C), and triglycerides. In comparison with
statins, fenoﬁbrate signiﬁcantly reduced prednisolone use.
Unfortunately, the author has described neither changes in
composite disease activity measures nor clinical response
rates after fenoﬁbrate therapy [49].
8.Conclusion
There is a substantial body of data suggesting that PPARα
may be of beneﬁt in patients with RA due to their anti-
inﬂammatory and lipid-modulating properties. Proof-of-
concept studies are needed to assess eﬃcacy and safety of
PPARα agonists in autoimmune diseases including RA and
to address the issues arising from our current understating
of PPARα agonists pharmacology (Table 2).
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